The Nasdaq debut follows private funding rounds
Windward Bio, a Swiss biotechnology company developing treatments for immune-related diseases, started trading on the Nasdaq stock exchange on 13 November. Its shares were offered at 17 dollars each.[1], [2]
Qiming Venture Partners, an investor in the company, said the shares ended their first trading session at 28.50 dollars, approximately 68 per cent above the offer price. It put the company’s equity market value at approximately 1.69 billion dollars. Qiming had invested in the Series A funding round in 2025, the Series B round in 2026 and the public offering.[1]
